SOURCE: IBC Life Sciences

January 09, 2008 15:54 ET

IBC Announces the 6th Annual Targeting Metabolic Disorders Conference

Advancing the Efficacy, Safety and Specificity of Metabolic Disease Therapeutics

WESTBOROUGH, MA--(Marketwire - January 9, 2008) - IBC's 6th annual conference, Targeting Metabolic Disorders -- to be held March 17th through the 19th, 2008 in Chapel Hill, NC -- provides a comprehensive look at scientific issues related to the targeting, safety and efficacy of metabolic disease therapeutics. The conference includes presenters from both industry and academia covering next-generation diabetes targets, novel delivery methods for peptide therapeutics, and new tools to study and treat metabolic disorders.

This year's Targeting Metabolic Disorders also features dedicated sessions on cardiometabolic effects of metabolic disease drugs, challenging drug targets, systems biology and metabolomics, and regulatory factors (secreted proteins) as drug targets. Important industry advances to be presented:

--  Roche reviews progress in resolving safety and efficacy challenges
    associated with small molecule obesity targets that affect lipid metabolism
--  Incyte reviews a proof-of-concept human study showing evidence for
    metabolic improvements in T2D subjects after short-term 11beta-HSD1
    inhibition therapy
--  Pennsylvania State University presents new research to further
    understandings of the role of macrophages and cytokines in insulin
--  GlaxoSmithKline outlines a novel high-resolution form of body
    composition analysis used to measure the pathophysiology of metabolic
    diseases and the effects of novel drugs
--  AstraZeneca describes the pros and cons of different methods for the
    PET imaging of beta cell mass
--  University of North Carolina shows progress in developing systems
    biology tools for understanding intervention points in MAP Kinase signaling

Each day of the conference features a different keynote speaker beginning with Clifford J. Rosen, M.D., Senior Scientist, St. Joseph Hospital, Member, FDA Endocrine Advisory Board. Jon Arch, Ph.D., Deputy Director of Metabolic Research, University of Buckingham, United Kingdom will present on the second day and a keynote address from Christopher B. Newgard, Ph.D., Distinguished Professor, Duke University Medical Center, will kick off the final day of the conference.

For complete conference information please visit,

Contact Information

  • Contact:
    Steve Garofalo
    IBC Life Sciences
    Email Contact